PhosphoPlus® TGF-beta Receptor I (Ser165) Antibody Duet #92722
Product Information
Kit Usage Information
Protocols
- 26664: Western Blotting
- 49728: Western Blotting, Immunoprecipitation (Magnetic)
Product Description
Background
Ligand banding and activation of type I receptor phosphorylates the protein at Ser165 and across a glycine, serine, threonine-rich domain (GS domain) at Thr185, Thr186, Ser187, Ser189, and Ser191 (9). Phosphorylation at Ser165 is not critical for transmission of TGF-β signals for transcription, cell growth, or migration, but is required for TGF-β-mediated extracellular matrix (ECM) formation and apoptotic signaling (9). Rottlerin, an activator of Ca2+-activated K+ channels, was shown to suppress TGF-β RI phosphorylation at Ser165 in in vitro and in vivo models of liver fibrosis, resulting in downregulation of pro-fibrotic TGF-β/Smad signaling (10). Overexpression of decorin, an ECM-protective protein, in hepatocullar carcinoma cells increased TGF-β RII expression and TGF-β RI phosphorylation at Ser165, suppressing the proliferation of these cells (11).
- Massagué, J. et al. (2000) Cell 103, 295-309.
- de Caestecker, M.P. et al. (2000) J Natl Cancer Inst 92, 1388-402.
- Derynck, R. et al. (2001) Nat Genet 29, 117-29.
- Derynck, R. and Feng, X.H. (1997) Biochim Biophys Acta 1333, F105-50.
- Miyazono, K. et al. (2000) Adv Immunol 75, 115-57.
- Massagué, J. (2000) Nat Rev Mol Cell Biol 1, 169-78.
- Derynck, R. et al. (1998) Cell 95, 737-40.
- López-Casillas, F. et al. (1991) Cell 67, 785-95.
- Souchelnytskyi S et al. (1996) EMBO J 15, 6231-40.
- Yang L et al. (2020) Front Pharmacol 11, 165.
- Liu Y et al. (2016) Exp Ther Med 12, 2191-2195.
Limited Uses
Except as otherwise expressly agreed in a writing signed by a legally authorized representative of CST, the following terms apply to Products provided by CST, its affiliates or its distributors. Any Customer's terms and conditions that are in addition to, or different from, those contained herein, unless separately accepted in writing by a legally authorized representative of CST, are rejected and are of no force or effect.
Products are labeled with For Research Use Only or a similar labeling statement and have not been approved, cleared, or licensed by the FDA or other regulatory foreign or domestic entity, for any purpose. Customer shall not use any Product for any diagnostic or therapeutic purpose, or otherwise in any manner that conflicts with its labeling statement. Products sold or licensed by CST are provided for Customer as the end-user and solely for research and development uses. Any use of Product for diagnostic, prophylactic or therapeutic purposes, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with CST products or services, (c) not alter or remove from the Products any trademarks, trade names, logos, patent or copyright notices or markings, (d) use the Products solely in accordance with CST Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.